Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-03-28 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2018年度报告提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (323 characters) indicating that the 2018 Annual Report has been published and is available on the designated disclosure website. It does not contain the actual report or financial data but merely informs investors to check the report elsewhere. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA), not the Annual Report itself.
2019-03-28 Chinese
独立董事2018年度述职报告（周泽将）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2018. It includes descriptions of attendance at board and shareholder meetings, independent opinions on various company matters including audit firm reappointment, non-public stock issuance, employee stock ownership plans, related party transactions, financial assistance, and internal control evaluations. The content focuses on the independent director's duties, opinions, and oversight activities throughout the year, which is typical of an independent director's annual report or statement. It is not a full annual report (10-K), audit report, or earnings release. It is also not a simple announcement or certification but a substantive report on the independent director's activities and opinions for the year. This fits best with a Board/Management Information (MANG) filing, as it relates to board-level oversight and management information rather than financial results or regulatory filings. The document length (6038 characters) and detailed content support this classification with high confidence.
2019-03-28 Chinese
独立董事2018年度述职报告（曹进）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of 安徽安科生物工程（集团）股份有限公司 for the year 2018. It includes descriptions of attendance at board and shareholder meetings, independent opinions on various company matters including audit firm reappointment, non-public stock issuance, employee stock ownership plans, internal controls, financial assistance, and other governance-related activities. The report focuses on the independent director's duties, opinions, and oversight activities throughout the year, which aligns with a management or board-related report rather than a financial report or announcement. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is also not a simple announcement or certification but a substantive report on the independent director's activities and opinions. This fits best with the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document length (5864 characters) and content confirm it is a full report, not a brief announcement or certification.
2019-03-28 Chinese
2018年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It is issued by a certified public accounting firm (华普天健会计师事务所) and addresses the shareholders of 安徽安科生物工程(集团)股份有限公司. The content includes detailed audit opinions, basis for audit opinions, key audit matters such as goodwill impairment and capitalization of R&D expenses, responsibilities of management and auditors, and extensive financial statement notes. The document contains detailed financial statements and notes, indicating it is a standalone audit report rather than a full annual report or other filing. The length (15,000 characters) and detailed content confirm it is not a brief announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2018
2019-03-28 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It is issued by an accounting firm (华普天健会计师事务所) and addresses the effectiveness of internal controls related to financial reporting as of December 31, 2018. The document mentions compliance with the Ministry of Finance's 'Basic Norms of Enterprise Internal Control' and provides an independent assurance conclusion on the internal control effectiveness. It is not a full annual report or audit report but a standalone assurance report on internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal controls. The document length is short (1339 characters), but it contains substantive assurance content, not just an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2018
2019-03-28 Chinese
独立董事2018年度述职报告（张本照）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2018. It includes descriptions of the director's duties, attendance at board and shareholder meetings, independent opinions on various company matters including audit firm reappointment, non-public stock issuance, employee stock ownership plans, internal controls, related party transactions, financial assistance, and other governance and supervisory activities. The content is focused on the independent director's oversight and governance role during the fiscal year 2018, including audit committee activities and compliance with laws and regulations. This type of document is a formal report by a board member on their management and supervisory activities, which fits the category of Board/Management Information (MANG). It is not an annual report, audit report, or earnings release, but a management-related report on board activities and governance.
2019-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.